Skip to main content

Table 5 Secondary measures

From: An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

Outcome domain

Measure

Scale

MDD symptoms

MADRS [35] assessed at baseline and at 2, 4, 6, and 8 weeks time points

10 items, each clinician-rated on a 7-point Likert scale, summed to give a total score between 0 and 60

Compliance

Acceptability of trial assessment load

Percentage of assessments completed by assessment type